{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:46:57Z","timestamp":1784677617723,"version":"3.55.0"},"reference-count":34,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PNT"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Botulinum neurotoxin has remarkably transitioned from a food safety hazard and biological\nwarfare to an effective therapeutic drug. Currently, botulinum neurotoxins have seven serotypes\n(BoNT\/A-G) in the form of protein complexes produced by Clostridium, a gram-positive and sporeforming\nbacteria. The conversion of toxins into useful drug substances of choice using the biotechnological\nprocess is tremendously increasing. Recent studies have shown that Botulinum neurotoxin-A\n(BoNT\/A) has different biological activities and potencies in experimental and clinical conditions. They\nalso indicate that the manufacturing process influences the potency and efficacy of BoNT\/A drugs.\nThus, this review focuses on the following criteria: detailed Fed-batch operation that includes the upstream\nand downstream processing of BoNT\/A, the underlying mechanism behind the neurotoxic effect,\nand commercially available FDA-approved BoNT\/A products and their therapeutic uses. Still, some research\ngaps exist in the mechanism for the treatment of psychiatric disorders.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2211738511666230825150259","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:37:12Z","timestamp":1693294632000},"page":"99-107","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Industrial Production and Therapeutic Application of Botulinum\nNeurotoxin: The Role of C. botulinum Type A"],"prefix":"10.2174","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0708-2232","authenticated-orcid":true,"given":"S. Danish","family":"Kadir","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, The University of Texas Rio Grande Valley, Edinburg, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00702-015-1478-1","volume":"123","author":"Dressler D.","year":"2016","unstructured":"Dressler D.; Botulinum toxin drugs: Brief history and outlook. J Neural Transm  2016,123(3),277-279","journal-title":"J Neural Transm"},{"key":"ref=2","unstructured":"U.S. Department of Health and Human Services. 2021.About botulism. Available from:"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/0019-5154.60343","volume":"55","author":"Nigam P.K.","year":"2010","unstructured":"Nigam P.K.; Nigam A.; Botulinum toxin. Indian J Dermatol  2010,55(1),8-14","journal-title":"Indian J Dermatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3928\/0191-3913-19800101-06","volume":"17","author":"Scott A.B.","year":"1980","unstructured":"Scott A.B.; Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus  1980,17(1),21-25","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/978-1-4614-9453-9","author":"Keith A.F.","year":"2014","unstructured":"Keith A.F.;  Molecular aspects of botulinum neurotoxin  2014,4","journal-title":"Molecular aspects of botulinum neurotoxin"},{"key":"ref=6","unstructured":"National Institutes of Health. NCI Drug Dictionary. 2022. Available from:"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.18388\/abp.2013_2015","volume":"60","author":"Samul D.","year":"2013","unstructured":"Samul D.; Beneficial and harmful roles of bacteria from the clostridium genus. Acta Biochim Pol  2013,60(4),515-521","journal-title":"Acta Biochim Pol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.4103\/jpbs.jpbs_184_22","volume":"14","author":"Sonone T.P.","year":"2022","unstructured":"Sonone T.P.; Botox and dermal fillers in orthodontics: A review. J Pharm Bioallied Sci  2022,14(Suppl. 1),S60-S64","journal-title":"J Pharm Bioallied Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/281398a0","volume":"281","author":"Raatjes G.J.","year":"1979","unstructured":"Raatjes G.J.; Smelt J.P.; Clostridium botulinum can grow and form toxin at pH values lower than 4.6. Nature  1979,281(5730),398-399","journal-title":"Nature"},{"key":"ref=10","volume":"Vol. 3","author":"Whitcup S.","year":"2022","unstructured":"Whitcup S.; Hillcup M.;  Botulinum Toxin Therapy Handbook of Experimental Pharmacology  2022,Vol. 3","journal-title":"Botulinum Toxin Therapy Handbook of Experimental Pharmacology"},{"key":"ref=11","author":"Prager G.","year":"2018","unstructured":"Prager G.;  No Title  2018","journal-title":"No Title"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","volume":"10","author":"Frevert J.","year":"2010","unstructured":"Frevert J.; Content of botulinum neurotoxin in botox\u00aevistabel\u00ae, dysport\u00aeazzalure\u00ae, and xeomin\u00aebocouture. Drugs R D  2010,10(2),67-73","journal-title":"Drugs R D"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/10408410590912952","volume":"31","author":"Shukla H.D.","year":"2004","unstructured":"Shukla H.D.; Sharma S.K.; Clostridium botulinum: A bug with beauty and weapon. Crit Rev Microbiol  2004,31(1),11-18","journal-title":"Crit Rev Microbiol"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-9453-9","volume":"Vol.4","author":"Keith A.","year":"2014","unstructured":"Keith A.;  Foster (2014) Molecular aspects of Botulinum Neurotoxin  2014,Vol.4","journal-title":"Foster (2014) Molecular aspects of Botulinum Neurotoxin"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"8903","DOI":"10.1021\/bi060786z","volume":"45","author":"Fu Z.","year":"2006","unstructured":"Fu Z.; Chen S.; Baldwin M.R.; Light chain of botulinum neurotoxin serotype A: Structural resolution of a catalytic intermediate. Biochemistry  2006,45(29),8903-8911","journal-title":"Biochemistry"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.toxicon.2012.11.011","volume":"67","author":"Tighe A.P.","year":"2013","unstructured":"Tighe A.P.; Schiavo G.; Botulinum neurotoxins: Mechanism of action. Toxicon  2013,67,87-93","journal-title":"Toxicon"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1177\/1090820X13487372","volume":"33","author":"Lorenc Z.P.","year":"2013","unstructured":"Lorenc Z.P.; Kenkel J.M.; Fagien S.; IncobotulinumtoxinA (Xeomin): Background, mechanism of action, and manufacturing. Aesthet Surg J  2013,33(1),18S-22S","journal-title":"Aesthet Surg J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/16501960310010151","volume":"35","author":"Barnes M.","year":"2003","unstructured":"Barnes M.; Botulinum toxin - mechanisms of action and clinical use in spasticity. J Rehabil Med  2003,35(41 Suppl),56-9","journal-title":"J Rehabil Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1056\/NEJMp020071","volume":"347","author":"Rowland L.P.","year":"2002","unstructured":"Rowland L.P.; Stroke, spasticity, and botulinum toxin. N Engl J Med  2002,347(6),382-383","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.tins.2005.06.001","volume":"28","author":"Davletov B.","year":"2005","unstructured":"Davletov B.; Bajohrs M.; Binz T.; Beyond BOTOX: Advantages and limitations of individual botulinum neurotoxins. Trends Neurosci  2005,28(8),446-452","journal-title":"Trends Neurosci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00702-007-0869-3","volume":"115","author":"Rosales R.L.","year":"2008","unstructured":"Rosales R.L.; Chua-Yap A.S.; Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm  2008,115(4),617-623","journal-title":"J Neural Transm"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.oftale.2022.06.011","volume":"97","author":"Maroto Rodr\u00edguez B.","year":"2022","unstructured":"Maroto Rodr\u00edguez B.; Stoica B.T.L.; Toledano Fern\u00e1ndez N.; Genol Saavedra I.; Treatment for functional epiphora with botulinum toxin-A versus lateral tarsal strip in a randomized trial. Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)  2022,97(10),549-557","journal-title":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/toxins12050332","volume":"12","author":"Spiegel L.L.","year":"2020","unstructured":"Spiegel L.L.; Ostrem J.L.; Bledsoe I.O.; FDA approvals and consensus guidelines for botulinum toxins in the treatment of dystonia. Toxins  2020,12(5),332","journal-title":"Toxins"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40257-020-00532-0","volume":"21","author":"Alster TS","year":"2020","unstructured":"Alster TS; Harrison IS; Alternative clinical indications of botulinum toxin. Am J Clin Dermatol  2020,21(6),855-80","journal-title":"Am J Clin Dermatol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00415-021-10613-7","volume":"269","author":"Hess K.","year":"2022","unstructured":"Hess K.; Schmitt M.; Wabbels B.; Periorbital injections of botulinum toxin a: A novel therapeutic option for convergence spasm in neuro-psychiatric disorders. J Neurol  2022,269(1),243-250","journal-title":"J Neurol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ane.13600","volume":"145","author":"Argyriou A.A.","year":"2022","unstructured":"Argyriou A.A.; Dermitzakis E.V.; Vlachos G.S.; Vikelis M.; Long\u2010term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis. Acta Neurol Scand  2022,145(6),676-683","journal-title":"Acta Neurol Scand"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1002\/nau.25012","volume":"41","author":"Clarkson B.D.","year":"2022","unstructured":"Clarkson B.D.; Karim H.T.; Chermansky C.J.; Changes in brain response to urgency before and after treatment of urgency urinary incon-tinence with onabotulinumtoxin A. Neurourol Urodyn  2022,41(8),1703-1710","journal-title":"Neurourol Urodyn"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.25259\/CSDM_49_2022","volume":"2","author":"Moftah N.H.","year":"2022","unstructured":"Moftah N.H.; Moftah N.H.; Non-pharmacologic treatment for acne vulgaris. CosmoDerma  2022,2,51","journal-title":"CosmoDerma"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e717","DOI":"10.1016\/j.jormas.2022.05.016","volume":"123","author":"Rasteau S.","year":"2022","unstructured":"Rasteau S.; Savoldelli C.; Winter C.; Lerhe B.; Castillo L.; Kestemont P.; Botulinum toxin type A for the treatment of excessive gingival display \u2013 A systematic review. J Stomatol Oral Maxillofac Surg  2022,123(6),e717-e723","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1468-3083.2007.02457.x","volume":"22","author":"Zanchi M.","year":"2008","unstructured":"Zanchi M.; Favot F.; Bizzarini M.; Piai M.; Donini M.; Sedona P.; Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol  2008,22(4),431-436","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.eururo.2008.08.048","volume":"55","author":"Giannantoni A.","year":"2009","unstructured":"Giannantoni A.; Mearini E.; Del Zingaro M.; Porena M.; Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: Clinical and urodynamic results. Eur Urol  2009,55(3),705-712","journal-title":"Eur Urol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jaad.2007.01.009","volume":"56","author":"Lowe N.J.","year":"2007","unstructured":"Lowe N.J.; Glaser D.A.; Eadie N.; Daggett S.; Kowalski J.W.; Lai P.Y.; Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: A 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol  2007,56(4),604-611","journal-title":"J Am Acad Dermatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/toxins13060370","volume":"13","author":"Dressler D.","year":"2021","unstructured":"Dressler D.; Pan L.; Su J.; Teng F.; Jin L.; Lantox\u2014The chinese botulinum toxin drug\u2014complete english bibliography and] comprehensive formalised literature review. Toxins  2021,13(6),370","journal-title":"Toxins"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.3390\/toxins7114519","volume":"7","author":"Pellett S.","year":"2015","unstructured":"Pellett S.; Yaksh T.; Ramachandran R.; Current status and future directions of botulinum neurotoxins for targeting pain processing. Toxins  2015,7(11),4519-4563","journal-title":"Toxins"}],"container-title":["Pharmaceutical Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2211738511666230825150259","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/220386\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2211738511666230825150259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T10:08:26Z","timestamp":1712657306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/220386\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2211738511666230825150259","relation":{},"ISSN":["2211-7385"],"issn-type":[{"value":"2211-7385","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}